Status:
COMPLETED
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (even...
Eligibility Criteria
Inclusion
- Type 2 diabetes for at least 12 months
- Currently treated with Oral Antidiabetic Drugs
- BMI lesser than or equal to 40 kg/m2
- HbA1c greater than or equal 7.5 and lesser than or equal to 11%
Exclusion
- Proliferative retinopathy or maculopathy
- Recurrent major hypoglycaemia
- uncontrolled hypertension or any disease or condition (such as renal, hepatic or cardiac) that according to the judgement of the Investigator makes the subject unsuitable for participation in the trial
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
503 Patients enrolled
Trial Details
Trial ID
NCT00104182
Start Date
February 1 2005
End Date
February 1 2006
Last Update
January 30 2017
Active Locations (96)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35235
2
Novo Nordisk Investigational Site
Mesa, Arizona, United States, 85205
3
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85029
4
Novo Nordisk Investigational Site
Anaheim, California, United States, 92801